Medidata and Sanofi Vaccine partners to enable remote patient monitoring with real-time data collection

Medidata, a subsidiary of Dassault Systèmes, a leading provider of clinical trial solutions for the life sciences industry, and Sanofi Vaccines, have collaborated to utilize the electronic diary (eDiary) function in eCOA to create an electronic diary database dedicated to Sanofi vaccines. The repository will help speed up deployment time for future studies, increase efficiency and improve data quality, while ensuring the electronic diary is patient-friendly.

Sanofi has partnered with Medidata for more than ten years, and has been using Medidata's solutions to securely and efficiently collect and manage research data across the enterprise, including vaccine research. With the extention of collaberation furthur the Sanofi vaccine research will make extensive use of Medidata eCOA solution by furthur expanding the usage of Medidata Rave EDC (electronic data capture)in the long standing partnership. Collaboration will help improve the patient experience and benefit patients in current research, patient monitoring while accelerating future research timelines and improving efficiency

Sanofi will be using eCOA in its vaccine studies to optimize the patient clinical experience by reducing on-site monitoring and allowing patients to enter data in real time from any location. Six recent vaccine pilot studies containing eCOA have demonstrated good patient compliance and high reliability of data. Based on this, the two parties have transformed from a pilot cooperation to a formal expansion of cooperation, and eCOA has now been widely used in various vaccine clinical trials of Sanofi.

Sanofi Head of Global Clinical Data Management for Vaccines said "With a customized e-diary repository, we are able to optimize the e-diary configuration in current trials and improve data quality, moving forward in the digital age of the pharmaceutical industry."

As part of the unified Medidata Platform , eCOA reduces research database construction time by nearly 50%, while providing a comprehensive view of patient data and giving patients the flexibility and choice to participate in clinical trial activities.